Dr Hedy Kindler presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the POLO trial.
This was a phase III randomised trial in which olaparib was administered to patients with BRCA-related pancreatic cancer who had not progressed after initial chemotherapy and compared with placebo.
After two years 22.1% of people receiving olaparib had no disease progression compared with 9.6% for those treated with placebo.
Watch the interview here.
Watch a comment from Dr. Suzanne Cole here.